A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
Status:
Completed
Trial end date:
2010-03-04
Target enrollment:
Participant gender:
Summary
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when
used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL). This study
will use a standard treatment regimen of Rituximab in combination with rising doses of
SB-485232. The dose selected from this study will be used in a future studies.